Basic Herbal Medicine Research Group, Korea Institute of Oriental Medicine, 483 Expo-ro, Yusung-gu, Daejeon 305-811, Republic of Korea.
J Ethnopharmacol. 2013 Aug 26;149(1):281-7. doi: 10.1016/j.jep.2013.06.036. Epub 2013 Jun 28.
Ojeok-san, a traditional Korean herbal medicine, is widely used in China, Japan and Korea for treatment of the common cold, pain and fever.
In this study, we investigated the protective effects of Ojeok-san aqueous extract (OJS) against pulmonary fibrosis using a chronic asthma murine model.
Mice were sensitized by intraperitoneal injection of ovalbumin (OVA), followed 1 weeks later by an airway challenge with OVA delivered three times a week for 4 weeks. OJS (50mg/kg or 100mg/kg) was also administered by oral gavage once a day for 4 weeks.
OJS significantly reduced interleukin (IL)-4, IL-13, eotaxin, immunoglobulin E and the number of inflammatory cells in bronchoalveolar lavage fluid; in addition, it reduced inflammatory cell infiltration and mucus production in the respiratory tract. We found that OJS also attenuated the OVA-induced increase in vascular endothelial growth factor (VEGF), transforming growth factor (TGF)-β1 and Smad3 protein in lung tissue, as determined by Western analysis and immunohistochemistry. These inhibitory effects of OJS were accompanied by a reduction in pulmonary fibrosis, consistent with the histopathology of lung tissue stained with Masson's trichrome.
Administration of OJS reduced the airway inflammation and pulmonary fibrosis, as well as the level of T helper type 2 cytokines and VEGF and TGF-β1/Smad3 expressions in lung tissue. These results suggest that OJS might represent a useful new oral therapy for the treatment of chronic asthma.
Ojeok-san,一种传统的韩国草药,在中国、日本和韩国被广泛用于治疗感冒、疼痛和发热。
本研究旨在通过慢性哮喘小鼠模型,研究 Ojeok-san 水提物(OJS)对肺纤维化的保护作用。
通过腹腔注射卵清蛋白(OVA)对小鼠进行致敏,1 周后,每周 3 次用 OVA 进行气道攻击,持续 4 周。OJS(50mg/kg 或 100mg/kg)也通过口服灌胃每天给药 1 次,持续 4 周。
OJS 显著降低白细胞介素(IL)-4、IL-13、嗜酸性粒细胞趋化因子、免疫球蛋白 E 和支气管肺泡灌洗液中的炎症细胞数量;此外,它还减少了呼吸道中的炎症细胞浸润和粘液产生。我们发现,OJS 还减弱了 OVA 诱导的肺组织血管内皮生长因子(VEGF)、转化生长因子(TGF)-β1 和 Smad3 蛋白的增加,这通过 Western 分析和免疫组织化学确定。OJS 的这些抑制作用伴随着肺纤维化的减少,与用 Masson 三色染色的肺组织的组织病理学一致。
OJS 的给药减少了气道炎症和肺纤维化,以及肺组织中 Th2 细胞因子和 VEGF 和 TGF-β1/Smad3 表达的水平。这些结果表明,OJS 可能代表一种用于治疗慢性哮喘的有用的新口服疗法。